Baseline characteristics of the SEER-Medicare–matched cohorts
| Characteristics* . | MDS/CMML . | Representative medicare† . | Solid malignancy . |
|---|---|---|---|
| n = 19 940 . | n = 39 880 . | n = 39 880 . | |
| Age, median (IQR)‡ | 78 (72-83) | 78 (72-83) | 77 (72-83) |
| Sex‡ | |||
| Male | 10 569 (53) | 21 136 (53) | 21 136 (53) |
| Female | 9 371 (47) | 18 744 (47) | 18 744 (47) |
| Race§ | |||
| White | 17 348 (87) | 33 898 (85) | 34 696 (87) |
| Black | 1 197 (6) | 2 580 (6) | 2 871 (7) |
| Other | 599 (3) | 1603 (4) | 1 356 (3) |
| Asian | 598 (3) | 1 635 (4) | 916 (2) |
| Unknown | 198 (1) | 164 (0) | 41 (0) |
| Ethnicity | |||
| Non-Hispanic | 19 142 (96) | 31 106 (78) | 37 886 (95) |
| Hispanic | 798 (4) | 8 375 (21) | 1 994 (5) |
| Data missing | — | 399 (1) | — |
| Myeloid malignancy subtype | |||
| CMML | 1 410 (7) | — | — |
| MDS | 18 530 (93) | — | — |
| NA | — | 39 880 (100) | 39 880 (100) |
| Year of index malignancy diagnosis‡ | |||
| 2000-2001 | — | — | 1 994 (5) |
| 2002-2005 | 5 384 (27) | 10 768 (27) | 10 369 (26) |
| 2006-2010 | 7 577 (38) | 15 154 (38) | 15 155 (38) |
| 2011-2015 | 6 979 (35) | 13 958 (35) | 12 362 (31) |
| Index malignancy is primary | |||
| Yes | 14 955 (75) | 7 976 (20) | 35 892 (90) |
| No | 4 985 (25) | 798 (2) | 3 988 (10) |
| No malignancy diagnosis|| | — | 31 106 (78) | — |
| Outpatient visits, median (IQR)¶ | 4 (1-9) | 1 (0-4) | 2 (1-6) |
| NCI comorbidity index¶ | |||
| 0 | 16 426 (47) | 41 154 (59) | 38 585 (55) |
| 1 | 7 966 (23) | 14 636 (21) | 16 407 (23) |
| 2 | 4 667 (13) | 7 204 (10) | 7 707 (11) |
| ≥3 | 5 910 (17) | 6 944 (10) | 7 239 (10) |
| Characteristics* . | MDS/CMML . | Representative medicare† . | Solid malignancy . |
|---|---|---|---|
| n = 19 940 . | n = 39 880 . | n = 39 880 . | |
| Age, median (IQR)‡ | 78 (72-83) | 78 (72-83) | 77 (72-83) |
| Sex‡ | |||
| Male | 10 569 (53) | 21 136 (53) | 21 136 (53) |
| Female | 9 371 (47) | 18 744 (47) | 18 744 (47) |
| Race§ | |||
| White | 17 348 (87) | 33 898 (85) | 34 696 (87) |
| Black | 1 197 (6) | 2 580 (6) | 2 871 (7) |
| Other | 599 (3) | 1603 (4) | 1 356 (3) |
| Asian | 598 (3) | 1 635 (4) | 916 (2) |
| Unknown | 198 (1) | 164 (0) | 41 (0) |
| Ethnicity | |||
| Non-Hispanic | 19 142 (96) | 31 106 (78) | 37 886 (95) |
| Hispanic | 798 (4) | 8 375 (21) | 1 994 (5) |
| Data missing | — | 399 (1) | — |
| Myeloid malignancy subtype | |||
| CMML | 1 410 (7) | — | — |
| MDS | 18 530 (93) | — | — |
| NA | — | 39 880 (100) | 39 880 (100) |
| Year of index malignancy diagnosis‡ | |||
| 2000-2001 | — | — | 1 994 (5) |
| 2002-2005 | 5 384 (27) | 10 768 (27) | 10 369 (26) |
| 2006-2010 | 7 577 (38) | 15 154 (38) | 15 155 (38) |
| 2011-2015 | 6 979 (35) | 13 958 (35) | 12 362 (31) |
| Index malignancy is primary | |||
| Yes | 14 955 (75) | 7 976 (20) | 35 892 (90) |
| No | 4 985 (25) | 798 (2) | 3 988 (10) |
| No malignancy diagnosis|| | — | 31 106 (78) | — |
| Outpatient visits, median (IQR)¶ | 4 (1-9) | 1 (0-4) | 2 (1-6) |
| NCI comorbidity index¶ | |||
| 0 | 16 426 (47) | 41 154 (59) | 38 585 (55) |
| 1 | 7 966 (23) | 14 636 (21) | 16 407 (23) |
| 2 | 4 667 (13) | 7 204 (10) | 7 707 (11) |
| ≥3 | 5 910 (17) | 6 944 (10) | 7 239 (10) |
IQR, interquartile range; NA, not available.
Baseline characteristics ascertained from claims from months 0 to −12, relative to the index malignancy diagnosis/pseudodiagnosis. All characteristics are presented as n (%), unless otherwise specified.
Representative Medicare cohort derived from a 5% random sample of Medicare recipients and excludes individuals with a history of hematologic malignancy.
Variables used in matching.
Race derived from Medicare claims.
Of the representative Medicare controls subjects, 78% had no diagnosis of a malignancy.
Calculated from outpatient visits in months 0 to −12 relative to the index malignancy diagnosis/pseudodiagnosis.